Patent EA-003371-B1 (EA)
Title: Use of biogenic estrogen sulfamates for hormone replacement therapy
Inventor: ELGER WALTER
IPC: A61K31/565
Filed: 1999-05-13
Abstract: 1. Use of biogenic estrogen sulfamates for the production of pharmaceutical agents for oral, intermittent administration for hormone replacement therapy, whereby the individual administrations have an interval of 2 to 40 days. 2. Use of biogenic estrogen sulfamates according to claim 1, characterized in that the biogenic estrogen sulfamate is estrone sulfamate, estradiol sulfamate, estriol sulfamate or an N-acylsulfamate of estrone, estradiol or estriol with up to 7 C atoms in the acyl chain or a combination of two or more of the above-mentioned active ingredients. 3. Use according to one of the preceding claims, wherein in addition at least one gestagen is administered. 4. Use according to claim 3, wherein the gestagen is levonorgestrel, desogestrel, norethisterone, medroxyprogesterone acetate, megestrol, cyproterone acetate, chlormadinone acetate, dienogest, drospirenone or a combination of two or more of the above-mentioned active ingredients. 5. Use according to claim 4, wherein the gestagen is administered continuously in the form of an implant or in the form of an intrauterine release system (IUD) or in combination with the above-mentioned types of administration. 6. Use according to one of claims 1 to 5, wherein the administration interval is 5 to l0 days, and the individual dosage unit for the administration interval is 0.5-5.0 mg of biogenic estrogen sulfamate. 7. Use according to one of claims 1 to 5, wherein the administration interval is 20 to 40 days, and the individual dosage unit for the administration interval is 2.0-20.0 mg of biogenic estrogen sulfamate. 8. Pharmaceutical composition that contains at least one biogenic estrogen, optionally combined with pharmaceutically compatible adjuvants and vehicles, wherein the individual dosage unit is 20-300 mug of biogenic estrogen sulfamate for an administration interval of 1 to 3 days, 0.5-5.0 mg of biogenic estrogen sulfamate for an administration interval of 5 to 10 days or 2.0-20 mg of biogenic estrogen sulfamate for an administration interval of 20 to 40 days. 9. Pharmaceutical composition according to claim 8, wherein the biogenic estrogen sulfamate is estrone sulfamate, estradiol sulfamate, estriol sulfamate or an N-acylsulfamate of estrone, estradiol or estriol with up to 7 C atoms in the acyl chain or a combination of two or more of the above-mentioned active ingredients. 10. Pharmaceutical composition according to one of claims 8 and/or 9, wherein in addition at least one gestagen is administered. 11. Pharmaceutical composition according to claim 10, wherein the gestagen is levonorgestrel, desogestrel, norethisterone, medroxyprogesterone acetate, megestrol, cyproterone acetate, chlormadinone acetate, dienogest, drospirenone or a combination of two or more of the abovementioned active ingredients. 12. Pharmaceutical composition according to claim 11, wherein the gestagen is administered continuously in the form of an implant or in the form of an intrauterine release system (IUD) or combined with the above-mentioned types of administration.